Novartis is a diversified healthcare company and our uniquely broad business portfolio focuses on science-based healthcare sectors that are growing, reward innovation and enhance the lives of patients. In Australia the Novartis group of companies includes:
- Novartis Animal Health
- Novartis Consumer Health
- Novartis Pharmaceuticals
- Vaccines and Diagnostics
We employ over 700 people in Australia and invest more than AUD 24million annually in local research. This research assures the quality of the company’s current range of treatments as well as the promise of improving future health outcomes.
Innovation is fundamental to our business. In 2010, we invested 16% of global net sales across our divisions in R&D and we will sustain our high level of investment. Novartis is consistently rated as having one of the industry’s most respected pharmaceutical development pipelines with more than 130 projects in pharmaceutical clinical development. Our mission is to care and cure.
Our success depends on the creativity and performance of our associates.
On March 7th, 1996 Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis.